Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related... see more

Recent & Breaking News (NDAQ:APLS)

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 21, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm

Accesswire August 20, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 19, 2023

APELLIS PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS

PR Newswire August 18, 2023

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLS

Newsfile August 18, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apellis Pharmaceuticals, Inc. - APLS

PR Newswire August 18, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 18, 2023

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)

Business Wire August 18, 2023

APLS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apellis Pharmaceuticals, Inc.

Accesswire August 18, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 17, 2023

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

PR Newswire August 17, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 17, 2023

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)

Business Wire August 17, 2023

APLS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apellis Pharmaceuticals, Inc.

Accesswire August 17, 2023

APLS LAWSUIT ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire August 17, 2023

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 16, 2023

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Apellis Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 2, 2023 - (NASDAQ: APLS)

PR Newswire August 16, 2023

APLS LOSS ALERT: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

Newsfile August 15, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 15, 2023

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Apellis Pharmaceuticals, Inc. (APLS) Investors

Business Wire August 15, 2023